Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Synaffix logo — A Lonza Company

Synaffix

A Lonza Company

Founded 2014 The Netherlands The Netherlands 63 employees Acquired Total: $100.00M Biotechnology, Health Care +1

General Information

Company Name Synaffix
Founded Year 2014
Location The Netherlands The Netherlands
Founders / Decision Makers
Team member Team member
Employees 63
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Acquired
Business Model B2B, Platform, API
Revenue Model Licensing, Service Fee, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Synaffix. To contact Synaffix, visit synaffix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Synaffix compare?

A PDF of Synaffix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Synaffix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Synaffix

Synaffix, a Lonza Company, is a pioneering biotech firm founded in 2014 and headquartered in The Netherlands. It boasts a proprietary, clinical-stage technology platform focused on antibody-drug conjugates (ADCs), renowned for optimizing safety and efficacy.

The platform's value is underscored by more than $7.6 billion in technology out-licensing deals with major partners such as ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, and Kyowa Kirin. These collaborations have resulted in the development of over 20 ADCs, with five already in Phase 1 clinical trials.

Synaffix's innovative platform is also addressing unmet medical needs in promising sectors like immune cell engagers and targeted gene therapy. Protected by patents until at least 2039, their technology offers an attractive proposition for investors. The firm's acquisition by Lonza in May 2023, following a €100 million investment from Onza Capital, further validates its potential in the biotechnology arena.

Business keywords: Antibody-Drug Conjugates, ADC Technology Platform, Licensed Partnerships, Biotech Innovation, Clinical-Stage Development, Enzymatic Glycan Modification, Metal-Free Click Chemistry, Site-Specific Conjugation, Cancer Therapeutics, Immune Cell Engagers, Targeted Gene Therapy, Bispecific Antibodies, Patent Portfolio, Phase 1 Clinical Trials, High Growth Market Segments

Services & Products

ADC Platform Licensing
Bispecific Antibody Development
Targeted Therapy Development
Out-licensing Technology for Cancer Therapeutics

Target Customers

Pharmaceutical Companies Biotechnology Firms Oncology Researchers Strategic Partners in Therapeutics

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition €100.00M 1
Onza Capital
Onza Capital
01 Jun 2023
Series A Undisclosed 1
M Ventures
M Ventures
01 Feb 2014
Spinout Undisclosed 1
University Ventures
University Ventures
01 Jul 2010

Synaffix Alternatives & Competitors

View All Alternatives
Synaffix vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Compare Synaffix vs Oxford BioTherapeutics
Synaffix vs
NextPoint Therapeutics, Inc.
NextPoint Therapeutics, Inc.

Launching a new world of precision therapeutics through its leading scientific work on the novel B7...

38 employees
Biotechnology, Health Care
Compare Synaffix vs NextPoint Therapeutics, Inc.
Synaffix vs
Araris Biotech AG
Araris Biotech AG Switzerland

Building tomorrow's antibody-drug conjugates (ADCs)

Grant
23 employees
Biotechnology, Health Care
Also compare with: Synaffix vs Bright Peak Therapeutics Bright Peak Therapeutics View all alternatives

FAQ About Synaffix

A Lonza Company
Synaffix was founded in 2014.
Synaffix is headquartered in The Netherlands.
Synaffix operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Antibody-Drug Conjugates, ADC Technology Platform, Licensed Partnerships and Biotech Innovation. Its customers include Pharmaceutical Companies, Biotechnology Firms and Oncology Researchers.
Synaffix has a B2B, Platform and API business model. Its revenue comes from Licensing, Service Fee and Performance Based.
Synaffix has approximately 63 employees.
Synaffix has completed 3 funding rounds, raising a total of $100.00M. The latest funding stage is Acquired.
Synaffix offers: ADC Platform Licensing, Bispecific Antibody Development, Targeted Therapy Development, Out-licensing Technology for Cancer Therapeutics.
Top alternatives and competitors to Synaffix include Oxford BioTherapeutics, NextPoint Therapeutics, Inc., Araris Biotech AG, Iksuda Therapeutics, Bright Peak Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Synaffix and Oxford BioTherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Synaffix, https://bouncewatch.com/company/synaffix-bv, updated 12 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes